The upgrade in the price target by a reputable analyst like Yaron Werber suggests a positive outlook on Ultragenyx Pharmaceutical's stock, likely due to anticipated performance improvements or positive developments within the company. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.